Improvement of endothelial injury

Improvement of endothelial injury" refers to strategies and agents aimed at restoring the health and function of vascular endothelial cells, which line the interior surface of blood vessels. Endothelial dysfunction is a common pathway linking inflammation, oxidative stress, and a variety of cardiovascular and metabolic diseases such as atherosclerosis, hypertension, and complications of diabetes, and is particularly prominent in severe COVID-19[1][4][5]. Therapeutic improvement commonly relies on anti-inflammatory, antioxidant, and antithrombotic agents—including statins, glucocorticoids, and prostacyclin analogs—each working through diverse molecular pathways such as inhibition of cytokine release (e.g., IL-6, IL-1β), stabilization of the endothelial glycocalyx, normalization of nitric oxide signaling, and reduction of oxidative stress. While improvement of endothelial injury is a therapeutic goal and not a discrete molecular target, drug development and biomarker assays continue to elucidate underlying molecular mediators and their relevance for patient stratification, therapeutic monitoring, and risk mitigation[1][2][3][4][5].

Anti-inflammatory activity, antioxidant effect, modulation of endothelial nitric oxide production, stabilization of glycocalyx, reduction of monocyte adhesion, inhibition of cytokine release, and activation of protective signaling (KLF2 overexpression, etc.).